COMPANY:

Memorial Sloan-Kettering Cancer Center

"ConcertAI's TeraRecon, the advanced visualization and clinical AI leader, recently unveiled first-in-category capabilities in advanced visualization, AI, and expansions to its AI partner ecosystem to enhance research capabilities and support complex clinical study workflows. These solutions will provide researchers with enhanced data analysis tools for in-depth study, contributing to more informed care strategies that can improve patient outcomes...As part of this announcement, ConcertAI is engaging in a multi-year strategic agreement with Memorial Sloan Kettering Cancer Center (MSKCC) focused on advancing Clinical AI in oncology, with an emphasis on enhancing clinical trials and improving oncology decision-making."

"SOPHiA GENETICS...announced that BioReference® Health, LLC...will implement SOPHiA GENETICS’ technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024."

"SOPHiA GENETICS...announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca...to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide....The partnership will provide MSK's proprietary liquid biopsy and solid tumor cancer tests – MSK-ACCESS^® and MSK-IMPACT^® – to organizations via the decentralized, technology-agnostic SOPHiA DDM™ Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca's global footprint."

"Caris Life Sciences® (Caris)...announced...that Memorial Sloan Kettering Cancer Center (MSK), one of the world’s premier cancer centers, has joined the Caris Precision Oncology Alliance™ (POA) and will collaborate with Caris on various research projects...The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Sophia Genetics said...that it has entered into a collaboration with New York's Memorial Sloan Kettering Cancer Center to combine predictive algorithms in a quest to offer new testing and analytical capabilities to cancer researchers and clinicians worldwide...Sophia will help the cancer center commercialize its MSK-ACCESS clinical liquid biopsy assay. Sophia said that the test will be the first circulating tumor DNA panel to be integrated with the company's flagship DDM analytics platform."

"Sophia Genetics said...that it has signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to collaborate on predictive tumor analysis and clinical decision support...With MSK, Sophia will contribute its CarePath multimodal analysis platform and other predictive algorithms to the New York-based cancer center's precision oncology databases to deliver actionable insights to MSK clinicians. The collaboration also gives Sophia's network of healthcare providers around the world access to the cancer center's proprietary tumor sequencing assays, including MSK-IMPACT."

"BostonGene said Tuesday that it has signed an agreement with Memorial Sloan Kettering Cancer Center to provide molecular laboratory and computational analysis services for several cancer precision medicine research initiatives...Under the master agreement, Waltham, Massachusetts-based BostonGene will contribute advanced analytics of next-generation sequencing data from the MSK-IMPACT sequencing test for solid tumors to look for new biomarkers and actionable targets in MSK's clinical and preclinical research programs."